170 related articles for article (PubMed ID: 15509456)
1. Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.
Dodick DW; Lipton RB; Ferrari MD; Goadsby PJ; McCrory D; Cutrer FM; Williams P
Curr Pain Headache Rep; 2004 Dec; 8(6):435-42. PubMed ID: 15509456
[TBL] [Abstract][Full Text] [Related]
2. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project).
Cutrer FM; Goadsby PJ; Ferrari MD; Lipton RB; Dodick DW; McCrory D; Williams P
Clin Ther; 2004 Sep; 26(9):1533-45. PubMed ID: 15531016
[TBL] [Abstract][Full Text] [Related]
3. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.
Lipton RB; Cutrer FM; Goadsby PJ; Ferrari MD; Dodick DW; McCrory D; Liberman JN; Williams P
Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210
[TBL] [Abstract][Full Text] [Related]
4. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management.
Goadsby PJ; Dodick DW; Ferrari MD; McCrory DC; Williams P
Acta Neurol Scand; 2004 Sep; 110(3):137-43. PubMed ID: 15285768
[TBL] [Abstract][Full Text] [Related]
5. Tripstar: a comprehensive patient-based approach to compare triptans.
Ferrari MD
Headache; 2002 Jan; 42 Suppl 1():18-25. PubMed ID: 11966860
[TBL] [Abstract][Full Text] [Related]
6. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
[TBL] [Abstract][Full Text] [Related]
7. The use of multiattribute decision models in evaluating triptan treatment options in migraine.
Ferrari MD; Goadsby PJ; Lipton RB; Dodick DW; Cutrer FM; McCrory D; Williams P
J Neurol; 2005 Sep; 252(9):1026-32. PubMed ID: 15761676
[TBL] [Abstract][Full Text] [Related]
8. Current perspectives on effective migraine treatments: are small clinical differences important for patients?
Ferrari MD
Drugs Today (Barc); 2003; 39 Suppl D():37-41. PubMed ID: 15071619
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the use of triptans in acute migraine.
Gawel MJ; Worthington I; Maggisano A
Can J Neurol Sci; 2001 Feb; 28(1):30-41. PubMed ID: 11252291
[TBL] [Abstract][Full Text] [Related]
10. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
Tfelt-Hansen P; De Vries P; Saxena PR
Drugs; 2000 Dec; 60(6):1259-87. PubMed ID: 11152011
[TBL] [Abstract][Full Text] [Related]
11. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
Ferrari MD; Roon KI; Lipton RB; Goadsby PJ
Lancet; 2001 Nov; 358(9294):1668-75. PubMed ID: 11728541
[TBL] [Abstract][Full Text] [Related]
12. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability.
Pascual J; Mateos V; Roig C; Sanchez-Del-Rio M; Jiménez D
Headache; 2007 Sep; 47(8):1152-68. PubMed ID: 17883520
[TBL] [Abstract][Full Text] [Related]
13. An economic evaluation of triptan products for migraine.
Perfetto EM; Weis KA; Mullins CD; Subedi P; Healey PJ
Value Health; 2005; 8(6):647-55. PubMed ID: 16283865
[TBL] [Abstract][Full Text] [Related]
14. Triptans for migraine management in adolescents.
Winner P
Headache; 2002; 42(7):675-9. PubMed ID: 12482222
[TBL] [Abstract][Full Text] [Related]
15. Naratriptan: an alternative for migraine.
Dulli DA
Ann Pharmacother; 1999 Jun; 33(6):704-11. PubMed ID: 10410185
[TBL] [Abstract][Full Text] [Related]
16. A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine.
Mondell BE
Clin Ther; 2003 Feb; 25(2):331-41. PubMed ID: 12749502
[TBL] [Abstract][Full Text] [Related]
17. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.
Dodick D; Lipton RB; Martin V; Papademetriou V; Rosamond W; MaassenVanDenBrink A; Loutfi H; Welch KM; Goadsby PJ; Hahn S; Hutchinson S; Matchar D; Silberstein S; Smith TR; Purdy RA; Saiers J;
Headache; 2004 May; 44(5):414-25. PubMed ID: 15147249
[TBL] [Abstract][Full Text] [Related]
18. Defining response in migraine: which endpoints are important?
Edmeads J
Eur Neurol; 2005; 53 Suppl 1():22-8. PubMed ID: 15920334
[TBL] [Abstract][Full Text] [Related]
19. Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study.
Solomon S; Frishberg B; Hu XH; Markson L; Berger M
Clin Ther; 2001 Jun; 23(6):886-900. PubMed ID: 11440288
[TBL] [Abstract][Full Text] [Related]
20. Triptans and migraine.
Bateman DN
Lancet; 2000 Mar; 355(9207):860-1. PubMed ID: 10752697
[No Abstract] [Full Text] [Related]
[Next] [New Search]
